METHODS
Feedback was obtained at the British HIV Association (BHIVA) annual conference, and subsequently through the UK PrEP Working eGroup, to which there is an open invitation to join. Two conference calls were arranged to solicit the opinions of organizations based in the community, and a meeting of stakeholders drawn from the eGroup was held on the 5 May 2011. Comments were solicited on the tables, and then the consensus statements. A further call was held on the 13 July 2011 to discuss the design of a randomized controlled trial (RCT). The tables and statements were updated to reflect new evidence that emerged in July, September and November 2011.
CONSENSUS STATEMENTS † HIV remains an infectious disease of major public health
importance in the UK with an estimated 91,500 individuals living with HIV at the end of 2010. 1 The epidemic most affects Black African, gay and other men who have sex with men (MSM) communities. In 2010, 3000 new infections were diagnosed in MSM (the highest ever total) and 2440 (81%) of these were judged to have been acquired within the UK; 1 † The majority of HIV prevention efforts in the UK have focused on behaviour change, mainly the use of condoms and, more recently, testing behaviour. There is limited funding for initiatives to be implemented in accordance with national guidelines, and increasing pressure to make savings. While cross-sectional data-sets of outcomes and impact provide some insight, there has been no systematic approach to the evaluation of behavioural interventions on a national basis; † Four randomized, placebo-controlled trials have now reported on the use of PrEP, providing evidence for the effectiveness of daily oral Truvada (tenofovir and emtricitabine) in MSM, 2 serodiscordant couples who were predominantly heterosexual, 3 young heterosexual adults 4 and coital tenofovir 1% vaginal gel in women. 5 A fifth trial of daily oral Truvada in women is conducting an orderly closure following an interim analysis which revealed equal numbers of HIV infections in the Truvada and placebo groups. 6 A sixth trial in women is similarly to discontinue daily oral tenofovir (September 2011) and daily tenofovir 1% vaginal gel (November 2011), but will continue daily oral Truvada and their respective placebo. 7 Other trials are underway or planned, one of these in the UK (Table 1) , available online only at: http://www.ijsa.rsmjournals.com/cgi/content/ full/23/1/1/DC1; † The momentum following these clinical trials creates the opportunity to re-think our overall strategy for HIV prevention at a time when the NHS is undergoing change. The continued increase in infections being identified in MSM acquired within the UK underscores the urgent need to do so. Central to the prevention strategy is full engagement of the most affected communities; 8 † A number of concerns have been expressed about the widespread use of PrEP in the UK by the gay communities, the sexual health-care commissioners, the regulatory authorities, clinicians and the research community. These concerns are common to other countries, and include cost, not only of drug but the feasibility of delivering it, the emergence of drug resistance, toxicity, and the possibility that people will drift away from consistent condom use or be pressured to do so by their partners and peers, outweighing any protection offered by PrEP.
CONCLUSION
It is imperative to gather evidence for the value of PrEP in the UK, in order to achieve universal access should it prove costeffective as part of a combination prevention package. There are important concerns, and we recommend that ad hoc prescribing is avoided, and that PrEP is only prescribed in the context of a clinical research study in the UK. Ideally, this would be a RCT, which is embedded in a broader concerted effort to intensify HIV prevention and implement the existing guidelines.
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Health-care workers should note that PrEP is one of several prevention tools and use the information in Table 2 to aid discussion of the options available to their service users. The data in support of condoms 10 and treatment of positive partners 11, 12 are too compelling to be ignored. While further evidence relevant to the UK setting is being gathered, validated behavioural interventions, regular HIV testing, the diagnosis and treatment of other sexually transmitted infections, and intensive health-promotion activities according to current BASHH-BHIVA guidelines should be implemented in preference to PrEP. Peter Scott, Ann Sullivan, Ben Tunstall and Helen Weiss -all of whom provided written feedback on the topic, and from contributions on the Community Calls.
